KDR and hypothyroidism: The incidence of hypothyroidism in monotherapy, combined chemotherapy, combined HDACi, and combined VEGFR TKI cohorts were 10.53% (4/38), 12.07% (7/58), 40.00% (2/5), and 37.50% (3/8), respectively.